Valuation: Wockhardt Limited

Market Cap 354B 3.69B 3.2B 3.02B 2.74B 5.14B 5.18B 36.08B 13.9B 180B 13.88B 13.57B 571B P/E 2025
-472x
P/E 2026 89.7x
Enterprise Value 370B 3.86B 3.34B 3.15B 2.86B 5.37B 5.41B 37.67B 14.51B 188B 14.49B 14.17B 596B EV / Sales 2025
8.1x
EV / Sales 2026 5.97x
Free-Float
48.98%
Yield 2025 *
-
Yield 2026 -
1 day-1.86%
1 week+4.34%
Current month+15.70%
1 month+13.93%
3 months+12.46%
6 months+79.92%
Current year+50.70%
1 week 2,166
Extreme 2166
2,272.9
1 month 1,814.4
Extreme 1814.4
2,272.9
Current year 1,086.7
Extreme 1086.7
2,422.3
1 year 1,086.7
Extreme 1086.7
2,422.3
3 years 213.25
Extreme 213.25
2,422.3
5 years 145.15
Extreme 145.15
2,422.3
10 years 145.15
Extreme 145.15
2,422.3
Manager TitleAgeSince
Chief Executive Officer 53 2009-03-31
Director of Finance/CFO - 2022-02-28
Chief Tech/Sci/R&D Officer - 1998-04-30
Director TitleAgeSince
Chairman 83 2009-11-05
Director/Board Member 53 2009-11-05
Director/Board Member 55 1996-06-30
Change 5-day change 1-year change 3-year change Capi.($)
-1.86%+4.34%+43.57%+767.94% 3.71B
-1.13%-3.11%+13.82%+60.17% 46.21B
-0.62%-6.36%+32.44%+108.15% 38.78B
+0.12%-0.08%+7.12%+73.98% 11.68B
-0.53%-1.37%-13.25%+11.19% 11.55B
+0.96%-1.32%+19.32%+145.33% 9.14B
+0.24%-1.18%+23.87%+35.93% 7.3B
+0.17%-0.74%+13.44%+180.68% 7.15B
+0.75%-4.53%+35.35%-18.67% 7.1B
+0.60%-3.72%-44.55%+13.55% 4.97B
Average -0.14%-1.60%+13.11%+137.83% 14.76B
Weighted average by Cap. -0.47%-2.93%+16.70%+92.36%

Financials

2025 2026
Net sales 30.35B 317M 274M 259M 235M 441M 444M 3.09B 1.19B 15.4B 1.19B 1.16B 48.95B 34.62B 361M 313M 295M 268M 503M 506M 3.53B 1.36B 17.56B 1.36B 1.33B 55.83B
Net income -470M -4.9M -4.25M -4.01M -3.64M -6.82M -6.87M -47.89M -18.45M -238M -18.42M -18.01M -758M 2.13B 22.22M 19.26M 18.17M 16.49M 30.93M 31.15M 217M 83.63M 1.08B 83.47M 81.63M 3.44B
Net Debt 14.33B 150M 130M 122M 111M 208M 210M 1.46B 563M 7.27B 562M 549M 23.11B 15.53B 162M 140M 132M 120M 225M 227M 1.58B 610M 7.88B 609M 595M 25.05B
Logo Wockhardt Limited
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Employees
2,564
Date Price Change Volume
26-09-11 ₹2,179.40 -1.86% 1,109,909
26-09-10 ₹2,220.60 -1.25% 693,525
26-09-09 ₹2,248.80 +1.12% 1,394,874
26-09-08 ₹2,224.00 +0.72% 1,343,981
26-09-07 ₹2,208.00 +5.71% 4,319,658
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. WOCKPHARMA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!